Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (51-60 of 162) with videos related to

Pageof 17
Sort By:
Brain, Behavior, and Immunity|December 16, 2014
Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findingsEbrahim Haroon, Jennifer C Felger, Bobbi J Woolwine, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 2014
IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopyEbrahim Haroon, Bobbi J Woolwine, Xiangchuan Chen, et al.
Expert Review of Hematology|August 1, 2020
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based reviewLarysa Sanchez, Kevin Barley, Joshua Richter, et al.
Pharmacogenomics and Personalized Medicine|December 26, 2024
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path ForwardMeghana Ram, Molly R Fraser, Junia Vieira Dos Santos, et al.
Oncotarget|February 26, 2015
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphomaVioletta V Leshchenko, Pei-Yu Kuo, Zewei Jiang, et al.
Annals of Hematology|October 3, 2020
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myelomaTarek H Mouhieddine, Samir Parekh, Hearn Jay Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 20, 2020
Myeloma CAR-T CRS Management With IL-1R Antagonist AnakinraShashidhar S Jatiani, Adolfo Aleman, Deepu Madduri, et al.
Blood|August 28, 2009
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndromeBritta Will, Masahiro Kawahara, Julia P Luciano, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2022
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor MicroenvironmentsNicolas Fernandez, Deepak Perumal, Adeeb Rahman, et al.
Blood Neoplasia|July 1, 2026
Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignanciesJonathan J Park, Zachary M Avigan, Matthew B Dong, et al.
Pageof 17

Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
Brain, Behavior, and Immunity|December 16, 2014
Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findingsEbrahim Haroon, Jennifer C Felger, Bobbi J Woolwine, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 2014
IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopyEbrahim Haroon, Bobbi J Woolwine, Xiangchuan Chen, et al.
Expert Review of Hematology|August 1, 2020
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based reviewLarysa Sanchez, Kevin Barley, Joshua Richter, et al.
Pharmacogenomics and Personalized Medicine|December 26, 2024
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path ForwardMeghana Ram, Molly R Fraser, Junia Vieira Dos Santos, et al.
Oncotarget|February 26, 2015
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphomaVioletta V Leshchenko, Pei-Yu Kuo, Zewei Jiang, et al.
Annals of Hematology|October 3, 2020
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myelomaTarek H Mouhieddine, Samir Parekh, Hearn Jay Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 20, 2020
Myeloma CAR-T CRS Management With IL-1R Antagonist AnakinraShashidhar S Jatiani, Adolfo Aleman, Deepu Madduri, et al.
Blood|August 28, 2009
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndromeBritta Will, Masahiro Kawahara, Julia P Luciano, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2022
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor MicroenvironmentsNicolas Fernandez, Deepak Perumal, Adeeb Rahman, et al.
Blood Neoplasia|July 1, 2026
Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignanciesJonathan J Park, Zachary M Avigan, Matthew B Dong, et al.
Pageof 17